The Effect of Prophylactic Nepafenac 0.1% Eye Drops on Macular Changes after Phacoemulsification in Non- Proliferative Diabetic Retinopathy Patients Using Spectral Domain Optical Coherence Tomography (SD-OCT)
Article Sidebar
Abstract
Background: To evaluate the effect of prophylactic nepafenac eye drops on macular thickness changes after phacoemulsification surgery in mild to moderate NPDR patients.
Method: This study is an open label randomized clinical trial. Thirty-six subjects who met the inclusion criteria underwent phacoemulsification. One group (18 subjects) were given nepafenac 0.1% eye drops and the rest were given placebo. Foveal thickness was measured by SD-OCT before surgery and the fourth week after phacoemulsification. Best corrected visual acuity (BCVA) and degree of inflammation in the anterior chamber were also being assessed.
Result: There was a statistically significant increase foveal thickness in the placebo group 4 weeks after phacoemulsification (p=0.022). Clinically, percentage degree of inflammation in anterior chamber in placebo group was higher than nepafenac group (38.9% : 5.6%) but not significantly different between 2 groups (p=0.27). Nepafenac group achieved clinically better BCVA than the placebo group 4 weeks after phacoemulsification, although statistically there was no significant difference between 2 groups (p=0.991).
Conclusion: Nepafenac 0.1% eye drops could prevent foveal thickening 4 weeks after phacoemulsification in mild to moderate NPDR patients. Clinically, nepafenac 0.1% eye drops could decrease the risk of inflammation in the anterior chamber, risk of CME, and vision deterioration although did not reach statistically significant.
Keywords: Nepafenac, macular thickness, phacoemulsification, retinopathy diabetic
Full text article
References
2. Sya’baniah UN, Andayani G, Djatikusumo A. Penelitian deskriptif: Prevalensi dan faktor risiko retinopati diabetik pada pasien diabetes mellitus berdasarkan skrining fotografi fundus di RS Cipto Mangunkusumo. 2012
3. Gupta A, Gupta V. Diabetic maculopathy and cataract surgery. Ophthalmol Clin of North America 2001;14:625-37
4. Romero-Aroca P, Fernandez-Ballart J, Almena-Garcia M, Mendez-Marin I, Salvat-Serra M, Buil-Calvo JA. Nonproliferative diabetic retinopathy and macular edema progression after phacoemulsification: prospective study. J Cataract Refract Surg 2006;32:1438–44
5. Miyake K, Ibaraki N. Prostaglandins and macular edema. Surv Ophthalmol 2002;47(Suppl 1):S203-18
6. Pollack A, Leiba H, Bukelman A, Oliver M. Cystoid macular edema following cataract extraction in patient with diabetes. Br J Ophthalmol 1992;76:221-4
7. Kim SJ, Equi R, Bressler NM. Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography. Ophthalmol 2007;114:881-9
8. Rosseti L, Chaudhuri J, Dickersin K. Medical prophylaxis and treatment of cystoid macular edema after cataract surgery; the results of meta analysis. Ophthalmol 1998;105:397-405
9. Almeida DR, Khan Z, Xing L, Bakar SN, Rahim K, Urton T et al. Prophylactic nepafenac and ketorolac versus plasebo in preventing postoperative macular edema after uneventful phacoemulsification, J Cataract Refract Surg 2012;38:1537–43
10. Risriwani D, Elvioza, Hutauruk J. Pengaruh meloxicam terhadap perubahan ketebalan makula pasca fakoemulsifikasi pada penderita non-proliferative diabetic retinopathy. Fakultas Kedokteran Universitas Indonesia. 2008
11. Walters T, Raizman M, Ernest P, Gayton J, Lehmann R. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and brofenac. J Cataract Refract Surg 2007; 33:1539-45
12. Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM. Nepafrenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation 2000;24:371-84
13. Singh R, Alpern L, Jaffe GJ, Lehmann RP, Lim J, Reiser H et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clinical Ophthalmology 2012;6:1259-69
14. Klein R, Klein BEK, Moss SE, Cruickshanks KJ. The winconsin epidemiologic study diabetic retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmol 1998;105:1801-15
15. Kohner EM. The effect of diabetic control on diabetic retinopathy. Eye 1993;7:309-11
16. Dholakia SA, Vasavada AR. Intraoperative performance and longterm outcome of phacoemulsification in age relatedcataract. Indian J of Ophthalmol 2004;54(4):311-7
17. Han IC, Jaffe GJ. Comparison of spectral- and time-domain optical coherence tomography for retinal thickness measurements in healthy and diseased eyes. Am J Ophthalmol 2009; 147: 847-58
18. Dacosta S, Rajendran B, Janakiraman P. In: spectral domain OCT. India: Jaypee Brothers Medical Publishers; 2008.p17-25
19. Lindstrom R, Kim T. Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac.Current Medical Research and Opinion 2006; 20(2): 397-404
20. Nardi M. Nepafenac in the prevention and treatment of ocular inflammation and pain following cataract surgery and in the prevention pf post-operative macular oedema in diabetic patients. European Ophthalmic Review 2012;6(3):169-72
21. Wolf EJ, Braunstein A, Shih C, Braunstein RE. Incident of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenac. J Cataract Refract Surg 2007;33:1546-9
22. Lane SS, Modi SS, Lehmann RP, Holland EJ. Nepafenac ophthalmic suspension 0.1 % for the prevention and treatment of ocular inflammation associated with cataract surgery. J Cataract Refract Surg 2007;33:53-8.
23. Nicholas S, Riley A, Patel H, Neveldson B, Purdie G, Wells AP. Correlations beteween optical coherence tomographymeasurement of macular thickness and visualacuity after cataract extraction. Clin Axp Ophthalmol 2006;80:468-77.